VEGF is a Target Molecule for Peritoneal Metastasis and Malignant Ascites in Gastric Cancer: Prognostic Significance of VEGF in Ascites and Efficacy of Anti-VEGF Monoclonal Antibody

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2013 Nov 9

PMID 24204159

Citations 21

Authors

Sachio Fushida

Katsunobu Oyama

Jun Kinoshita

Yasumichi Yagi

Kouichi Okamoto

Hidehiro Tajima

Itasu Ninomiya

Takashi Fujimura

Tetsuo Ohta

Affiliations

Soon will be listed here.

Abstract

Background: In gastric cancer, poor prognosis is associated with peritoneal dissemination, which often accompanies malignant ascites. We searched for a target molecule in peritoneal metastasis and investigated its clinical utility as a biomarker.

Methods: Biopsy specimens from both primary lesions and peritoneal metastasis, and if possible, malignant ascites, were obtained from 40 patients with gastric cancer. Vascular endothelial growth factor (VEGF) expression was analyzed by immunohistochemical staining and enzyme-linked immunosorbent assay.

Results: VEGF expression was seen in 70% of peritoneal samples. Of the 40 patients, 35 had malignant ascites. These 35 patients were divided into two groups: 15 with ascites found beyond the pelvic cavity (large group) and 20 whose ascites were within the pelvic cavity (small group). The two groups did not significantly differ by serum VEGF levels, but ascites VEGF levels in the large group were significantly higher than in the small group (P < 0.0001). Serum VEGF and ascites VEGF levels were highly correlated in the large group (r = 0.686). A high ascites VEGF level was found to be a risk factor for survival (P = 0.045). We include a report of a patient with chemoresistant refractory gastric cancer and symptomatic ascites who obtained 8 months of palliation from systemic bevacizumab.

Conclusion: Anti-VEGF therapies are promising, and the ascites VEGF level is an important marker in managing patients with gastric cancer and peritoneal metastasis.

Citing Articles

Peritoneal high-fat environment promotes peritoneal metastasis of gastric cancer cells through activation of NSUN2-mediated ORAI2 m5C modification.

Liu K, Xu P, Lv J, Ge H, Yan Z, Huang S Oncogene. 2023; 42(24):1980-1993.

PMID: 37130916 DOI: 10.1038/s41388-023-02707-5.

Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study.

Matsumoto T, Yamamura S, Ikoma T, Kurioka Y, Doi K, Yasuda T Clin Med Insights Oncol. 2022; 16:11795549221137135.

PMID: 36408335 PMC: 9666830. DOI: 10.1177/11795549221137135.

ADAM10 and ADAM17 as Biomarkers Linked to Inflammation, Metabolic Disorders and Colorectal Cancer.

Sikora-Skrabaka M, Walkiewicz K, Nowakowska-Zajdel E, Waniczek D, Strzelczyk J Curr Issues Mol Biol. 2022; 44(10):4517-4527.

PMID: 36286024 PMC: 9600049. DOI: 10.3390/cimb44100309.

A novel form of docetaxel polymeric micelles demonstrates anti-tumor and ascites-inhibitory activities in animal models as monotherapy or in combination with anti-angiogenic agents.

Guo L, Qin X, Xue L, Yang J, Zhang Y, Zhu S Front Pharmacol. 2022; 13:964076.

PMID: 36091776 PMC: 9449419. DOI: 10.3389/fphar.2022.964076.

A novel oncolytic virus induces a regional cytokine storm and safely eliminates malignant ascites of colon cancer.

Dong S, Liu B, Hu S, Guo F, Zhong Y, Cai Q Cancer Med. 2022; 11(22):4297-4309.

PMID: 35510373 PMC: 9678102. DOI: 10.1002/cam4.4772.

References

Connolly D, Heuvelman D, Nelson R, Olander J, Eppley B, Delfino J . Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989; 84(5):1470-8. PMC: 304011. DOI: 10.1172/JCI114322. View

Li B, Lalani A, Harding T, Luan B, Koprivnikar K, Tu G . Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res. 2006; 12(22):6808-16. DOI: 10.1158/1078-0432.CCR-06-1558. View

Sadeghi B, Arvieux C, Glehen O, Beaujard A, Rivoire M, Baulieux J . Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000; 88(2):358-63. DOI: 10.1002/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o. View

Byrne A, Ross L, Holash J, Nakanishi M, Hu L, Hofmann J . Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res. 2003; 9(15):5721-8. View

Li L, Wang L, Zhang W, Tang B, Zhang J, Song H . Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 2004; 24(3b):1973-9. View

Yagi Y, Fushida S, Harada S, Tsukada T, Kinoshita J, Oyama K . Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice. Cancer Chemother Pharmacol. 2009; 66(4):745-53. DOI: 10.1007/s00280-009-1219-y. View

Kamiyama M, Ichikawa Y, Ishikawa T, Chishima T, Hasegawa S, Hamaguchi Y . VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. Cancer Gene Ther. 2002; 9(2):197-201. DOI: 10.1038/sj.cgt.7700428. View

Karayiannakis A, Syrigos K, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C . Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg. 2002; 236(1):37-42. PMC: 1422546. DOI: 10.1097/00000658-200207000-00007. View

Bamias A, Koutsoukou V, Terpos E, Tsiatas M, Liakos C, Tsitsilonis O . Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based.... Gynecol Oncol. 2007; 108(2):421-7. DOI: 10.1016/j.ygyno.2007.10.018. View

10.

Rudlowski C, Pickart A, Fuhljahn C, Friepoertner T, Schlehe B, Biesterfeld S . Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer. 2006; 16 Suppl 1:183-9. DOI: 10.1111/j.1525-1438.2006.00307.x. View

11.

Baba M, Konno H, Maruo Y, Tanaka T, Kanai T, Matsumoto K . Relationship of p53 and vascular endothelial growth factor expression of clinicopathological factors in human scirrhous gastric cancer. Eur Surg Res. 1998; 30(2):130-7. DOI: 10.1159/000008568. View

12.

Sherer D, Eliakim R, Abulafia O . The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female. Gynecol Obstet Invest. 2000; 50(4):217-24. DOI: 10.1159/000010320. View

13.

Zhang X, Zhu X, Gao J, Qian C, Kuang Z, Liu Z . Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165. Acta Pharmacol Sin. 2001; 22(8):731-5. View

14.

Maeda K, Chung Y, Ogawa Y, Takatsuka S, Kang S, Ogawa M . Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996; 77(5):858-63. DOI: 10.1002/(sici)1097-0142(19960301)77:5<858::aid-cncr8>3.0.co;2-a. View

15.

Chu D, Lang N, Thompson C, Osteen P, Westbrook K . Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989; 63(2):364-7. DOI: 10.1002/1097-0142(19890115)63:2<364::aid-cncr2820630228>3.0.co;2-v. View

16.

Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O . Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem. 1994; 269(9):6271-4. View

17.

Yonemura Y, Endo Y, Yamaguchi T, Fujimura T, Obata T, Kawamura T . Mechanisms of the formation of the peritoneal dissemination in gastric cancer. Int J Oncol. 2011; 8(4):795-802. DOI: 10.3892/ijo.8.4.795. View

18.

Harmey J, Dimitriadis E, Kay E, Redmond H, Bouchier-Hayes D . Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol. 1998; 5(3):271-8. DOI: 10.1007/BF02303785. View

19.

Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S . Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett. 2000; 153(1-2):7-12. DOI: 10.1016/s0304-3835(99)00426-7. View

20.

Vidal O, Metges J, Elizalde I, Valentini M, Volant A, Molina R . High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg. 2009; 96(12):1443-51. DOI: 10.1002/bjs.6780. View